Showing 19,681 - 19,700 results of 42,081 for search '(( a point decrease ) OR ( 50 ((((we decrease) OR (a decrease))) OR (mean decrease)) ))', query time: 1.04s Refine Results
  1. 19681

    Table_1_Nematode communities along a bathymetric transect in the deep eastern Fram Strait (Arctic Ocean): interrelations between diversity, function and environment.xlsx by Jannik Schnier (17602938)

    Published 2023
    “…Nematode densities generally decreased with increasing depth. Taxonomic diversity (EG<sub>(50)</sub>, H’<sub>(log2)</sub>, J’) decreased in a unimodal pattern peaking in the lower bathyal zone. …”
  2. 19682
  3. 19683

    DataSheet2_Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models.pdf by Andrea Mancini (4254934)

    Published 2025
    “…</p>Methods<p>The aim of this study was to investigate in vitro and in vivo the potential of ABTL0812, an oral anticancer compound currently in phase II clinical stage, as a novel therapy for GBM.</p>Results<p>We showed that ABTL0812 inhibits cell proliferation in a wide panel of GBM cell lines and patient-derived glioblastoma stem cells (GSCs) with half maximal inhibitory concentrations (IC50s) ranging from 15.2 µM to 46.9 µM. …”
  4. 19684

    DataSheet_2_Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models.pdf by Andrea Mancini (4254934)

    Published 2022
    “…</p>Methods<p>The aim of this study was to investigate in vitro and in vivo the potential of ABTL0812, an oral anticancer compound currently in phase II clinical stage, as a novel therapy for GBM.</p>Results<p>We showed that ABTL0812 inhibits cell proliferation in a wide panel of GBM cell lines and patient-derived glioblastoma stem cells (GSCs) with half maximal inhibitory concentrations (IC50s) ranging from 15.2 µM to 46.9 µM. …”
  5. 19685

    DataSheet1_Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models.pdf by Andrea Mancini (4254934)

    Published 2025
    “…</p>Methods<p>The aim of this study was to investigate in vitro and in vivo the potential of ABTL0812, an oral anticancer compound currently in phase II clinical stage, as a novel therapy for GBM.</p>Results<p>We showed that ABTL0812 inhibits cell proliferation in a wide panel of GBM cell lines and patient-derived glioblastoma stem cells (GSCs) with half maximal inhibitory concentrations (IC50s) ranging from 15.2 µM to 46.9 µM. …”
  6. 19686

    DataSheet_1_Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models.pdf by Andrea Mancini (4254934)

    Published 2022
    “…</p>Methods<p>The aim of this study was to investigate in vitro and in vivo the potential of ABTL0812, an oral anticancer compound currently in phase II clinical stage, as a novel therapy for GBM.</p>Results<p>We showed that ABTL0812 inhibits cell proliferation in a wide panel of GBM cell lines and patient-derived glioblastoma stem cells (GSCs) with half maximal inhibitory concentrations (IC50s) ranging from 15.2 µM to 46.9 µM. …”
  7. 19687

    Data_Sheet_1_The Effects of a 6-Week Controlled, Hypocaloric Ketogenic Diet, With and Without Exogenous Ketone Salts, on Body Composition Responses.pdf by Alex Buga (10361168)

    Published 2021
    “…Whether augmenting ketosis with KS impacts body composition responses to a well-formulated KD remains unknown.</p><p>Purpose: To explore the effects of energy-matched, hypocaloric KD feeding (<50 g carbohydrates/day; 1.5 g/kg/day protein), with and without the inclusion of KS, on weight loss and body composition responses.…”
  8. 19688

    Data Sheet 1_Non-linear association between the dietary index for gut microbiota and the atherogenic index of plasma: insights from a cross-sectional study.docx by Tian-Ding Liu (21659201)

    Published 2025
    “…Each one-point increase in DI-GM was associated with a 0.007-point reduction in AIP (95% CI: −0.012 to −0.002). …”
  9. 19689

    Data_Sheet_1_A novel chimeric endolysin Cly2v shows potential in treating streptococci-induced bovine mastitis and systemic infections.docx by Shuang Wang (46453)

    Published 2024
    “…Notably, in a mouse mastitis model, treatment with Cly2v (50 μg/gland) led to a reduction in bacterial load by 2.16 log<sub>10</sub>CFU/ml and decreased inflammatory cytokine levels in mammary tissue. …”
  10. 19690
  11. 19691

    Gene expression profiling, for genes involved in regulating cell cycle, in A549, MCF-7 and HepG2 cells incubated with or without etoposide under normoxic or hypoxic conditions by Jean-Philippe Cosse (37121)

    Published 2011
    “…Each value is the average of three ratio values calculated from three independent experiments ± 1 S.D. Mean ratios indicate a fold-increase or decrease in gene expression. …”
  12. 19692

    Image_1_Global, Regional, and National Burden of Myocarditis From 1990 to 2017: A Systematic Analysis Based on the Global Burden of Disease Study 2017.TIF by Xiqiang Wang (5955647)

    Published 2021
    “…</p><p>Results: The incidence cases of myocarditis in 2017 was 3,071,000, with a 59.6% increase from 1990, while the age-standardized incidence rate (ASIR) was slightly decreased. …”
  13. 19693

    Table_4_Global, Regional, and National Burden of Myocarditis From 1990 to 2017: A Systematic Analysis Based on the Global Burden of Disease Study 2017.docx by Xiqiang Wang (5955647)

    Published 2021
    “…</p><p>Results: The incidence cases of myocarditis in 2017 was 3,071,000, with a 59.6% increase from 1990, while the age-standardized incidence rate (ASIR) was slightly decreased. …”
  14. 19694

    Image_2_Global, Regional, and National Burden of Myocarditis From 1990 to 2017: A Systematic Analysis Based on the Global Burden of Disease Study 2017.TIF by Xiqiang Wang (5955647)

    Published 2021
    “…</p><p>Results: The incidence cases of myocarditis in 2017 was 3,071,000, with a 59.6% increase from 1990, while the age-standardized incidence rate (ASIR) was slightly decreased. …”
  15. 19695

    Table_3_Global, Regional, and National Burden of Myocarditis From 1990 to 2017: A Systematic Analysis Based on the Global Burden of Disease Study 2017.docx by Xiqiang Wang (5955647)

    Published 2021
    “…</p><p>Results: The incidence cases of myocarditis in 2017 was 3,071,000, with a 59.6% increase from 1990, while the age-standardized incidence rate (ASIR) was slightly decreased. …”
  16. 19696

    Table_1_Global, Regional, and National Burden of Myocarditis From 1990 to 2017: A Systematic Analysis Based on the Global Burden of Disease Study 2017.docx by Xiqiang Wang (5955647)

    Published 2021
    “…</p><p>Results: The incidence cases of myocarditis in 2017 was 3,071,000, with a 59.6% increase from 1990, while the age-standardized incidence rate (ASIR) was slightly decreased. …”
  17. 19697

    Table_2_Global, Regional, and National Burden of Myocarditis From 1990 to 2017: A Systematic Analysis Based on the Global Burden of Disease Study 2017.docx by Xiqiang Wang (5955647)

    Published 2021
    “…</p><p>Results: The incidence cases of myocarditis in 2017 was 3,071,000, with a 59.6% increase from 1990, while the age-standardized incidence rate (ASIR) was slightly decreased. …”
  18. 19698

    Image_3_Global, Regional, and National Burden of Myocarditis From 1990 to 2017: A Systematic Analysis Based on the Global Burden of Disease Study 2017.TIF by Xiqiang Wang (5955647)

    Published 2021
    “…</p><p>Results: The incidence cases of myocarditis in 2017 was 3,071,000, with a 59.6% increase from 1990, while the age-standardized incidence rate (ASIR) was slightly decreased. …”
  19. 19699
  20. 19700